Alembic Pharmaceuticals Limited has reported a strong start to FY27, posting a 26% year-on-year increase in consolidated revenue from operations to Rs. 2,150 crore for the quarter ended June 30, 2026, driven by robust growth across domestic and international businesses.

The company reported profit after tax (PAT) of Rs. 173 crore, up 12% from the corresponding quarter last year. EBITDA before R&D expenditure stood at Rs. 523 crore, with an EBITDA margin of 24%.

Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said, “We have started FY27 on a strong note, delivering broad-based growth across our businesses. Performance during the quarter was driven by healthy volume growth, successful new product launches and continued execution across key markets. The US business delivered strong momentum, and the rest of the markets also recorded steady growth. We remain focused on strengthening our product portfolio, advancing our pipeline and driving sustainable long-term growth.”

The India Branded Business recorded 7% year-on-year growth, with revenue reaching Rs. 642 crore. The company said its gynaecology, gastrology and ophthalmology portfolios delivered robust growth during the quarter, while its animal healthcare business also registered encouraging performance. Alembic introduced three new products in the domestic market during the period.

The company's international business continued to be the key growth driver. US formulations revenue surged 49%to Rs. 778 crore, supported by seven product launches during the quarter. The Ex-US generics business grew 17%to Rs. 383 crore, while the company received 10 ANDA approvals from the US Food and Drug Administration during the quarter.

Alembic's Active Pharmaceutical Ingredients (API) business also delivered a strong performance, with revenue increasing 33% year-on-year to Rs. 346 crore.

The company said it remains focused on expanding its product portfolio, strengthening its development pipeline and driving sustainable long-term growth across domestic and global markets.